Research: DALL and BAYS,

Listed in Issue 175

Abstract

DALL and BAYS,  Advanced Lipidology, Delafield, WI 53018, USA. earlydetection@advlip.com review [46 References] the role of statins and omega-3 fatty acids for decreasing very high triglyceride (TG) levels.

Background

Decreasing very high triglyceride (TG) levels (>or=500 mg/dL) is recommended to prevent pancreatitis.

Methodology

Decreasing low-density lipoprotein cholesterol (LDL-C) is the primary lipid treatment target to reduce the risk of atherosclerotic coronary heart disease. A secondary lipid treatment target for patients at LDL-C goal, but with persistent TG elevations, includes achievement of non-high density lipoprotein cholesterol goals (non-HDL-C). Statins are the mainstay of therapy to lower LDL-C, but statin monotherapy may not achieve all lipid treatment goals.

Results

Thus, in patients with multiple lipid abnormalities, combination lipid-altering therapy is often necessary. Drugs such as niacin and fibrates provide lipid benefits beyond LDL-C when used in combination with a statin.

Conclusion

Prescription omega-3-fatty acids combined with statin therapy also provide improvements in lipid parameters beyond cholesterol alone. [References: 46]

References

Dall TL and Bays H. Addressing lipid treatment targets beyond cholesterol: a role for prescription omega-3 fatty acid therapy. [Review] [46 refs]. Southern Medical Journal. 102(4):390-6. Apr 2009.

ICAN 2024 Skyscraper

Scientific and Medical Network 2

Cycle Around the World for Charity 2023

Climb Mount Kilimanjaro Charity 2023

top of the page